Project Grant R01CA289250
Award Date
2/21/25
Completion Date
1/31/30
Dollars Obligated
$679K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This federal Project Grant award in the amount of $684,367 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research to identify intratumoral microbiome profiles and spatial immune signatures that can predict response to immune checkpoint inhibitor (ICI) therapy in non-small cell lung cancer patients. The awardee, Baylor College of Medicine, will analyze pre-treatment tumor samples from three independent patient cohorts (N=500) using...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program is providing $147,486 to Baylor College of Medicine to investigate a novel immune tolerization strategy for studying the trade-offs between oncogene pathogenicity and immunogenicity. The project aims to uncouple an oncogene's pathogenic potential from its immunogenic properties, enabling the dissection of genetic and phenotypic alterations that govern immune evasion independently of...
This $244,228 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports a research initiative to develop a functional proteomics approach for accurately mapping lung cancer patient tumors to preclinical models. The key products and services to be delivered include: Expanding the proteomic profiling of lung cancer patient-derived xenograft (PDX) models using a reverse-phase protein array (RPPA) platform that has...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $540,288 to the University of Florida to research the role of bacterial-derived small molecules in improving response to immune checkpoint inhibitor (ICI) treatment for non-small cell lung cancer (NSCLC). The key products/services to be delivered include: Defining the functional impact of the bacterial metabolite BAC429 on experimental NSCLC, including its immunostimulatory effects...
The National Cancer Institute (NCI) awarded a $696,569 Project Grant (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine to conduct research aimed at developing novel therapies for lung cancer. The project, titled "Targeting LCN2, a Novel Therapy for Lung Cancer," will characterize the role of the immunosuppressive molecule lipocalin 2 (LCN2) in the tumor microenvironment and develop therapeutic antibodies that interfere with LCN2 function. The goal is...
This $627,833 Project Grant award from the National Cancer Institute's Cancer Biology Research Program (CFDA 93.396) aims to develop an informatics platform that integrates molecular and pathological data from various lung cancer preclinical models and patient tumors. The key products and services to be delivered include: Harmonizing molecular profiling datasets from multiple lung cancer preclinical models and implementing statistical methods for cross-study validation and quality control....
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $225,101 to Baylor College of Medicine to investigate how the MYCN oncogene drives an immune-suppressive tumor microenvironment in neuroblastoma. The research aims to (1) determine how MYCN rewires T cell metabolism to promote immune suppression, and (2) elucidate how MYCN-induced lipogenesis contributes to a suppressive tumor immune microenvironment. The project period runs...
The National Cancer Institute (NCI) awarded a $730,400 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research. The five-year grant, running from December 1, 2024 to November 30, 2029, will support research to determine how specific configurations of the tricarboxylic acid (TCA) cycle metabolic pathway contribute to the development and maintenance of treatment-resistant lung adenocarcinoma (LUAD) cell states. The research aims to...
This federal Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), aims to identify interception targets in persistent lung premalignant lesions (PMLs) to prevent lung cancer progression. The $566,523 award, granted on December 5, 2024, supports research to: 1) identify interception targets in the persistence profile of lung PMLs using clinical trial biopsies, 2) determine the effects of prevention agents like...
This Project Grant award of $158,365 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to understand the impact of NRF2 activation on lung squamous cell carcinoma (LUSC) initiation and progression. The University of North Carolina at Chapel Hill is the prime awardee and will develop a novel genetically-engineered mouse model to assess how activated NRF2 affects LUSC incidence, tumor characteristics, and the tumor microenvironment. The research aims to...